Home » Clinical Trials » Hemophilia » NCT03003533
NCT03003533

Gene-transfer, Open-label, Dose-escalation Study of SPK-8011 [Adeno-associated Viral Vector With B-domain Deleted Human Factor VIII Gene] in Individuals With Hemophilia A

Study Summary

This clinical research study is being conducted by Spark Therapeutics, Inc. to determine the safety and efficacy of the factor VIII gene transfer treatment with SPK-8011 in individuals with hemophilia A.

Want to learn more about this trial?

Request More Info

Interventions

SPK-8011GENETIC
A novel, bio-engineered, recombinant adeno-associated viral vector carrying human factor VIII gene

Study Locations

FacilityCityStateCountry
University of California Davis - Hemostasis and Thrombosis CenterSacramentoCaliforniaUnited States
University of Florida HealthGainesvilleFloridaUnited States
Boston Children's HospitalBostonMassachusettsUnited States
Mississippi Center for Advanced MedicineMadisonMississippiUnited States
Weill Cornell Medicine-Comprehensive Center for Hemophilia and Coagulation DisordersNew YorkNew YorkUnited States
Oregon Health & Science UniversityPortlandOregonUnited States
Pennsylvania State University Milton S. Hershey Medical CenterHersheyPennsylvaniaUnited States
Children's Hospital of PhiladelphiaPhiladelphiaPennsylvaniaUnited States
Jefferson University HospitalsPhiladelphiaPennsylvaniaUnited States
Hemophilia Center of Western PennsylvaniaPittsburghPennsylvaniaUnited States
Virginia Commonwealth University School of MedicineRichmondVirginiaUnited States
Royal Prince Alfred HosptialCamperdownNew South WalesAustralia
The Alfred HospitalMelbourneAustralia
McMaster University Medical Centre and Juravinski HospitalHamiltonOntarioCanada
Chaim Sheba CenterRamat GanTel HashomerIsrael
Mahidol University - Ramathibody HospitalBangkokThailand

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026